Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.

scientific article

Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/ARCHINTE.162.10.1164
P8608Fatcat IDrelease_3n7nwrhwy5dkfbbqozzbtcviwq
P698PubMed publication ID12020188

P50authorGuillermo Ruiz-IrastorzaQ37830875
Beverley J HuntQ59165686
Graham R. V. HughesQ73300356
Munther A. KhamashtaQ73418907
P2093author name stringMaria J Cuadrado
Alejandro Escudero
P433issue10
P407language of work or nameEnglishQ1860
P921main subjectthrombosisQ261327
antiphospholipid syndromeQ582207
anticoagulationQ63279445
P304page(s)1164-1169
P577publication date2002-05-01
P1433published inJAMA Internal MedicineQ177428
P1476titleBleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5.
P478volume162

Reverse relations

cites work (P2860)
Q95359426Q95359426
Q28174751A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
Q92797128Acute ST-elevation myocardial infarction in a young patient with antiphospholipid syndrome
Q73245534Antiphospholipid Antibody Syndrome
Q59808719Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy
Q28192380Antiphospholipid antibodies in young adults with stroke
Q41838557Antiphospholipid syndrome and recurrent thrombosis--limitations of current treatment strategies.
Q38596401Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review
Q38410376Antiphospholipid syndrome: an update
Q37729831Antiphospholipid syndrome: frequency, main causes and risk factors of mortality
Q40323287Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS).
Q35016262Association between CHADS₂risk factors and anticoagulation-related bleeding: a systematic literature review.
Q33422184Bleeding and thrombosis in a patient with primary antiphospholipid syndrome using norethisterone: a case report
Q35189299Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report
Q28196276Cerebrovascular disease associated with antiphospholipid antibodies: more questions than answers
Q37076800Controversies in the antiphospholipid syndrome: can we ever stop warfarin?
Q37642830Current management of antiphospholipid syndrome-related thrombosis
Q38818425Current status and future prospects for the treatment of antiphospholipid syndrome
Q36947358D-dimer level and the risk for thrombosis in systemic lupus erythematosus
Q24632951Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Q34157396Heparin and osteoporosis during pregnancy: 2002 update
Q45220914Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus
Q38856073IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis
Q38273875Intensity of anticoagulation in the treatment of thrombosis in the antiphospholipid syndrome: a meta-analysis
Q36458164Laboratory diagnosis and management challenges in the antiphospholipid syndrome
Q47286340Low molecular weight heparin to prevent antiphospholipid syndrome morbidity in pregnancy
Q46452620Management of end-stage renal disease patients with antiphospholipid antibody syndrome
Q33423034Management of the antiphospholipid syndrome
Q64910478Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults.
Q28174728Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes
Q90289969Multiple embolic strokes as a result of Libman-Sacks endocarditis associated with lupus and secondary antiphospholipid antibody syndrome: a case report
Q39198671Pathogenesis and management of antiphospholipid syndrome
Q40221778Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study).
Q64241805Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation
Q28071739Recommended Therapeutic INR Range for Patients with Antiphospholipid Syndrome on Warfarin Anticoagulation: Is Moderate-Intensity (INR 2.0 - 3.0) or High-Intensity (INR 3.1 - 4.0) Better for Reducing Risk of Recurrent Thromboembolic Events?
Q90401929Risk factors for ischemic stroke in patients with non-valvular atrial fibrillation and therapeutic international normalized ratio range
Q37477857Rituximab in lupus and beyond: the state of the art.
Q36832526Role of complement in antiphospholipid antibody-mediated thrombosis
Q35189292Stroke and the antiphospholipid syndrome: consensus meeting Taormina 2002.
Q37543887Successful Anticoagulation Therapy for Antiphospholipid Syndrome with Mobile Aortic Thrombi
Q37642828Thrombosis in systemic lupus erythematosus: risk and protection
Q28193706Treatment and monitoring of patients with antiphospholipid antibodies and thrombotic history (Hughes syndrome)
Q35621012Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management-An Insight into Future Approaches
Q43342883Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil).
Q35189289Venous thromboembolism in the antiphospholipid syndrome: management guidelines for secondary prophylaxis
Q84600032[Antiphospholipid syndrome treatment, to whom, when and how long?]

Search more.